Q2 2024 saw Abera Bioscience improve its financial position, launch a new lab in Uppsala, and advance its vaccine pipeline, supported by UK Vaccine Network funding. Net loss narrowed significantly year-over-year, with continued focus on financing for clinical trials.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.